Literature DB >> 29563590

Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.

Seung-Ah Yahng1, Sung-Soo Park2, Young-Woo Jeon2, Jae-Ho Yoon2, Seung-Hwan Shin3, Sung-Eun Lee2, Byung-Sik Cho2, Ki-Seong Eom2, Yoo-Jin Kim2, Seok Lee2, Chang-Ki Min2, Hee-Je Kim2, Seok-Goo Cho2, Dong-Wook Kim2, Woo-Sung Min2, Jong Wook Lee4.   

Abstract

Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The reconditioning regimen (TNI-750/ATG) consisted of a single dose of total nodal irradiation (TNI, 750 cGy) and antithymocyte globulin (ATG; Thymoglobulin®, 1.25 mg/kg/day for 3 days). All but one patient achieved successful engraftment of neutrophils (median 12 days, range 5-21) and platelets (median 15 days, range 9-316). Two patients with subsequent secondary GF achieved successful engraftment after a third HSCT from the same MSD. After a median follow-up of 57.4 months (range, 11.2-155.2), the 5-year overall survival and failure-free survival were 95.7% (95% confidence interval [CI] 87.7-100%) and 87.5% (95% CI 75.2-100%), respectively. One patient developed grade II acute graft-versus-host disease (GVHD), and the 2-year cumulative incidence of chronic GVHD was 23.5% (95% CI 8.1-43.5%). This study demonstrated successful outcomes following a second MSD HSCT in SAA after GF, and the results suggest TNI-750/ATG is a feasible reconditioning option. Future studies with larger cohorts will validate our results.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29563590     DOI: 10.1038/s41409-018-0154-0

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.

Authors:  D J Weisdorf; C M Verfaillie; S M Davies; A H Filipovich; J E Wagner; J S Miller; J Burroughs; N K Ramsay; J H Kersey; P B McGlave
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

Review 2.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

3.  Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis).

Authors:  A Stucki; W Leisenring; B M Sandmaier; J Sanders; C Anasetti; R Storb
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

4.  Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia.

Authors:  N K Ramsay; T H Kim; P McGlave; A Goldman; M E Nesbit; W Krivit; W G Woods; J H Kersey
Journal:  Blood       Date:  1983-09       Impact factor: 22.113

5.  Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results.

Authors:  R E Champlin; M M Horowitz; D W van Bekkum; B M Camitta; G E Elfenbein; R P Gale; E Gluckman; R A Good; A A Rimm; C Rozman
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

  5 in total
  2 in total

1.  Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia.

Authors:  Meijie He; Ruirui Gui; Yingling Zu; Zhen Li; Dao Wang; Yanna Mao; Xianjing Wang; Huili Wang; Yongping Song; Jian Zhou
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

2.  Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Authors:  Michael H Albert; Mehtap Sirin; Manfred Hoenig; Fabian Hauck; Catharina Schuetz; Rajat Bhattacharyya; Polina Stepensky; Elad Jacoby; Tayfun Güngör; Rita Beier; Ansgar Schulz
Journal:  Bone Marrow Transplant       Date:  2021-05-09       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.